Pathological complete response and survival after neoadjuvant chemotherapy in patients with stage I TNBC: a registry-based study.

ABSTRACT:

Background

Pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) is a strong prognostic factor in patients with early-stage triple-negative breast cancer (TNBC). One-third of all patients with early-stage TNBC have stage I disease. Chemotherapy is recommended for most patients with stage I TNBC with an increasing use in the neoadjuvant setting supported by recent guidelines. However, little is known on the chemotherapy benefit for stage I TNBC, in particular the likelihood of a pCR and the prognostic value of pCR in this setting.

Patients and methods

Patients with cT1N0M0 TNBC who received standard of care NACT followed by surgery between 2012 and 2022 were identified from the Netherlands Cancer Registry. Baseline factors associated with pCR (ypT0/is, yp

SUBMITTER: de Graaf M 

PROVIDER: S-EPMC12721258 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature